The management of refractory carcinoid syndrome: challenges and opportunities ahead

J Med Econ. 2018 Mar;21(3):241-243. doi: 10.1080/13696998.2017.1394312. Epub 2017 Nov 3.

Authors

Mauro Cives¹, Eleonora Pellè¹, Franco Silvestris¹

Affiliation

¹ a Department of Biomedical Sciences and Human Oncology , University of Bari 'Aldo Moro' , Bari , Italy.

PMID: 29039712
DOI: 10.1080/13696998.2017.1394312

No abstract available

Publication types

Review

MeSH terms

Cost-Benefit Analysis
Drug Therapy, Combination
Humans
Malignant Carcinoid Syndrome / drug therapy*
Octreotide / therapeutic use
Precision Medicine
Radiopharmaceuticals / therapeutic use
Somatostatin / analogs & derivatives*
Somatostatin / economics
Time Factors

Substances

Radiopharmaceuticals
Somatostatin
Octreotide